Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma

• Matteo Costacurta,
• Stephin J Vervoort,
• Simon J Hogg,
• Benjamin P Martin,
• Ricky W Johnstone,
• Jake Shortt

Affiliations

Matteo Costacurta

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne

Stephin J Vervoort

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne

Simon J Hogg

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne

Benjamin P Martin

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne

Ricky W Johnstone

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne

Jake Shortt

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville; Monash Haematology, Monash Health, Clayton; Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Clayton